Application of combination of chidamide and CGB as well as autologous hematopoietic stem cells and drug combination

A technology of hematopoietic stem cells and chidamide, which is applied in the application of chidamide combined with CGB and autologous hematopoietic stem cells and the field of combined drugs, can solve the problems of doubts about curative effect, poor curative effect, and inability of patients to get disease improvement, and achieve efficient treatment Effect

Pending Publication Date: 2020-06-05
SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Commonly used second-line regimens include those that have no cross-drug resistance with first-line regimens, have less impact on hematopoiesis, and do not affect subsequent stem cell collection, such as DICE, ICE, and GemOx regimens, for salvage treatment, but there are still a considerable number of patients who cannot get disease improvement
However, in the era when new drugs represented by MabThera participated in the treatment of lymphoma, the efficacy of relapsed and primary drug-resistant lymphoma patients receiving classic pretreatment chemotherapy such as BEAM regimen followed by autologous

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of chidamide and CGB as well as autologous hematopoietic stem cells and drug combination
  • Application of combination of chidamide and CGB as well as autologous hematopoietic stem cells and drug combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) regimen combined with autologous hematopoietic stem cell transplantation in the treatment of relapsed or refractory diffuse large B-cell lymphoma in multicenter, single-arm, open-label II phase clinical trial

[0018] Test drug:

[0019] Chidamide tablets: off-white tablets, 5mg / tablet. Produced by Shenzhen Microchip Biotechnology Co., Ltd.

[0020] Cladribine: water injection, 10mg / bottle. Manufactured by Zhejiang Hisun Pharmaceutical Co., Ltd.

[0021] Gemcitabine: Use commercially available drugs.

[0022] Busulfan: water injection, 60mg / bottle. Produced by Otsuka Pharmaceutical Research and Development (Beijing) Co., Ltd.

[0023] Number of cases: A total of 93 patients are planned to be enrolled in this clinical trial.

[0024] Inclusion criteria: Patients must meet all of the following criteria to be enrolled.

[0025] 1. Diffuse large B-cell lymphoma who did not obtain CR in the first-li...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of drugs, and discloses application of a combination of chidamide and CGB as well as autologous hematopoietic stem cells and a drug combination. The invention provides application of a treatment scheme of the combination of the chidamide and CGB as well as autologous hematopoietic stem cell transplantation which have a synergistic treatment effect on Bcell lymphoma. Clinical trials verify that PFS and OS of the scheme of the combination of the chidamide and CGB as well as the autologous hematopoietic stem cell transplantation for treating relapsedor refractory diffuse large B cell lymphoma are 81.7% and 100% respectively. By the application, patients suffering from the B cell lymphoma can be treated efficiently.

Description

[0001] This application claims the priority of the Chinese patent application submitted to the China Patent Office on November 27, 2018, with the application number 201811427194.8, and the title of the invention is "Chidamide Combined with CGB and Autologous Hematopoietic Stem Cell Application and Combined Drugs", all of which The contents are incorporated by reference in this application. technical field [0002] The invention relates to the technical field of medicines, in particular to the application of chidamide combined with CGB and autologous hematopoietic stem cells and combined medicines. Background technique [0003] B-cell lymphoma mainly includes diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), and mantle cell lymphoma (MCL). The existing R-CHOP regimen of rituximab (R) combined with cyclophosphamide (CTX), doxorubicin (ADR), vincristine (VCR), and prednisone (Pred) is the current treatment for diffuse large B-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4406A61K31/7076A61K31/7068A61K31/255A61K35/28A61P35/00
CPCA61K31/255A61K31/4406A61K31/7068A61K31/7076A61K35/28A61P35/00A61K2300/00
Inventor 鲁先平刘霆季杰付鑫
Owner SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap